Risedronate has no adverse effects on mouse haematopoiesis.
Bisphosphonates are commonly used for treatment of osteoporosis. They inhibit osteoclast activity and thus bone resorption. It was shown that they also affect some other cell types including tumour and endothelial cells. The effects of risedronate on bone marrow microenvironment were not studied yet. As endothelial cells are integral part of bone marrow microenvironment, it is important to know whether prolonged administration of bisphosphonates does not affect haematopoietic stem cells and bone marrow haematopoiesis. We fed mice two weeks with risedronate. We found no effect of risedronate treatment on bone marrow stem cells using the method of congenic bone marrow repopulation. Risedronate administration in the dose which is considered to be comparable to a dose of risedronate used for treatment of osteoporosis in women seems to be safe in terms of effects on mouse haematopoiesis.
Sefc
L
L
Institute of Pathophysiology, Charles University in Prague, 1st Faculty of Medicine, Prague, Czech Republic. sefc@cesnet.cz
Broulík
P
P
Pelichovská
T
T
Necas
E
E
D000818:Animals; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000494:pharmacology*; D001854:Bone Marrow Cells / Q000166:cytology / Q000187:drug effects; D016026:Bone Marrow Transplantation; D002118:Calcium / Q000097:blood; D012968:Etidronic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology; D006410:Hematopoiesis / Q000187:drug effects*; D007962:Leukocytes / Q000187:drug effects; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009929:Organ Size / Q000187:drug effects; D010710:Phosphates / Q000097:blood; D000068296:Risedronic Acid; D012669:Seminal Vesicles / Q000187:drug effects
D050071:Bone Density Conservation Agents; D010710:Phosphates; D000068296:Risedronic Acid; D012968:Etidronic Acid; D002118:Calcium